Ring Christine 4

What Happened Christine Ring, Chief Legal Officer of Nurix Therapeutics (NRIX), sold 14,261 shares in an open‑market transaction on February 9, 2026. The weighted average sale price was $16.66 per share for total gross proceeds of approximately $237,618. The reported sale price range was $16.37 to $16.88. This was a sale (S), which is often routine and does not itself indicate insider sentiment about the company’s prospects.

Key Details

• Transaction date: 2026-02-09
• Transaction type: Open-market sale (code S)
• Shares sold: 14,261
• Weighted average price: $16.66; price range: $16.37–$16.88 (footnote F2)
• Total proceeds (approx.): $237,618
• Shares owned after transaction: Not provided in the excerpt of the filing
• Footnotes: F1 — transaction executed under a previously adopted Rule 10b5-1 trading plan; F2 — weighted average noted and issuer can provide per-price breakdown on request
• Filing timeliness: Report filed on 2026-02-09 (same date as transaction), appears timely

Context A 10b5-1 trading plan allows insiders to sell shares according to a prearranged schedule, which can make such sales routine and reduce concerns about trading on nonpublic information. For retail investors, purchases by insiders tend to be a stronger bullish signal than routine sales; this single disclosed sale should be viewed as a disposition of shares under a preexisting plan rather than a definitive statement about company fundamentals.